fluorouridine

Fluorouridine (5-fluorouridine) is a fluorinated pyrimidine nucleoside analog that acts as an antimetabolite. It is the riboside form of 5-fluorouracil (5-FU). Within the cell, fluorouridine is phosphorylated to fluorouridine triphosphate (FUTP), which is incorporated into RNA, thereby disrupting RNA processing and protein synthesis. It can also be converted into metabolites that inhibit thymidylate synthase, an enzyme essential for DNA synthesis. While 5-fluorouracil is the more common clinical agent, fluorouridine and its derivatives are studied for their antineoplastic activity. In the context of clinical trials sponsored by Simcere Pharmaceutical, the term is often associated with chemotherapy regimens used in combination with envofolimab (a PD-L1 inhibitor) and suvemcitug (BD0801, a VEGF inhibitor) for advanced solid tumors, including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC). It is important to note that in many clinical settings, "5-fluorouridine" may be used as a shorthand or confused with 5-fluorouracil or the prodrug doxifluridine (Qi Nuo), which is marketed by Simcere.

Other names

5-fluorouridineFluorouridine1-beta-D-ribofuranosyl-5-fluorouracil